RemeGen Co., Ltd. (HKG: 9995)

Market Cap	12.24B
Revenue (ttm)	1.51B
Net Income (ttm)	-1.71B
Shares Out	537.91M
EPS (ttm)	-3.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,814,500
Open	12.14
Previous Close	12.46
Day's Range	11.92 - 12.46
52-Week Range	11.26 - 49.00
Beta	0.36
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials fo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3,615
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9995

Financial Performance

In 2023, RemeGen's revenue was 1.08 billion, an increase of 40.26% compared to the previous year's 772.11 million. Losses were -1.51 billion, 51.3% more than in 2022.

Financial numbers in CNY